Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2013 vs rituximab in previously untreated CD20-positive follicular lymphoma
jRCT2080222241Phase 3Completed
- Sponsor
- Sandoz
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Sandoz. Started Oct 2013; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2080222241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222241.